Qué financiamos (solo en inglés)

Funded projects
1,320+
Men's Health Partners
20
Countries
20
We work closely with our global men's health partners to ensure collaboration, transparency and accountability for every project we fund. We monitor this through report cards which detail what we seek to achieve, key measures and the impact.
Prostate Cancer
"Together with the brightest minds in research, we aim to achieve significant breakthroughs in the hope of beating prostate cancer. Our disruptive funding approach identifies revolutionary ways to accelerate health outcomes by creating strong, global collaborative teams." Dr. Colleen Nelson, Global Scientific Chair.
Men's Health
"One Mo can help change the face of men’s health through the powerful conversations created globally during Movember. Men have the chance to confidently discuss men’s health with people around them, resulting in men taking action early, helping change and save lives." Paul Villanti, Executive Director, Programmes
Mental health and suicide prevention
“The number of men taking their own lives around the world is one of the biggest challenges of our time. Movember is working to ensure all men and boys look after their mental health and are comfortable to seek help when they’re struggling.”
Brendan Maher, Global Director, Mental Health and Suicide Prevention.
Testicular Cancer
“Despite being the 2nd most common cancer in young men, testicular cancer is often a forgotten cancer due to early detection and treatment. Our projects look at underinvested areas such as improving access to healthcare services and treatment options for relapse” Paul Villanti, Executive Director, Programmes.

GAP1 Global Prostate Cancer Biomarker Initiative

Movember Funding to Date

Global funding AUD equivalent 12,600,623.71

What we seek to achieve

The aim of the project is to develop and validate new tests that better predict whether prostate cancer is aggressive or low risk so that patient treatment decisions can be optimized at the time of diagnosis.

Country
Spain
Implemented by
The Movember Foundation
Project start date
March 2011
Project Status
Completed July 2016

About the project

New tests (biomarkers) to distinguish low risk from aggressive prostate cancer and treatment resistance are desperately needed to improve outcomes for men with the disease.
  
Movember has brought researchers and clinicians together from around the world to address this challenge and accelerate the development of new blood, urine and tissue-based tests that optimize patient treatment decisions.  

Focused, integrated team-based research, performed across borders with a strong collaborative mindset is allowing researchers to share ideas and methodologies to optimize best practice in biomarker development.

This project has been governed by the GAP1 Project Research Advisory Committee.  This global committee of highly regarded experts in the field has guided and shaped the project.

(Local investment EUR 146,200)

>
Page 1 of 33